BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/21/2025 7:06:12 AM | Browse: 3 | Download: 15
 |
Received |
|
2025-06-19 04:11 |
|
Peer-Review Started |
|
2025-06-19 04:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-07-04 09:17 |
|
Revised |
|
2025-07-18 09:00 |
|
Second Decision |
|
2025-10-16 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-10-17 08:34 |
|
Articles in Press |
|
2025-10-17 08:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-10 08:46 |
|
Publish the Manuscript Online |
|
2025-11-21 07:06 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nassrin A Badroon, Abdulsamad Alsalahi, Musheer A Aljaberi, Nazia Abdul Majid and Mohammed Abdullah Alshawsh |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Malaysian Ministry of Higher Education through the Fundamental Research Grant Scheme |
FP103-2019 |
|
| Corresponding Author |
Mohammed Abdullah Alshawsh, PhD, Professor, Department of Pharmacology, Faculty of Medicine, University Malaya, University Malaya, Lembah Pantai, Kuala Lumpur 50603, Malaysia. alshaweshmam@um.edu.my |
| Key Words |
Cardamonin; Pharmacodynamics; Pharmacokinetics; Chalcones; Flavonoids; Anticancer; Preclinical studies |
| Core Tip |
This review summarizes preclinical studies on cardamonin, highlighting that pharmacokinetic studies show poor oral bioavailability, whereas pharmacodynamic findings demonstrate its antiproliferative, anti-metastatic, and chemosensitizing effects, primarily through inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells, mammalian target of rapamycin, signal transducer and activator of transcription 3, and Wnt/β-catenin signaling pathways. However, the limited in vivo toxicity data raise concerns about the balance between cardamonin’s therapeutic potential and safety, posing challenges for its translation from preclinical research to clinical application. |
| Publish Date |
2025-11-21 07:06 |
| Citation |
<p>Badroon NA, Alsalahi A, Aljaberi MA, Abdul Majid N, Alshawsh MA. Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications. <i>World J Clin Oncol</i> 2025; 16(11): 110911</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i11/110911.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i11.110911 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
